Press Releases

BC3 TECHNOLOGIES ANNOUNCES SEAL HEMOSTATIC WOUND SPRAY NOW ELIGIBLE FOR HSA AND FSA PURCHASE

-- Expanding Access to Life-Saving Bleed Control Through Pre-Tax Healthcare Spending --

(Baltimore, MD) – BC3 Technologies, a Baltimore-based, minority-owned company revolutionizing emergency medical response and trauma care, announces today that its SEAL Hemostatic Wound Spray is now eligible for purchase using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA), making advanced bleed control more accessible to consumers nationwide.

This milestone enables individuals, families, caregivers, and organizations to use pre-tax healthcare dollars to invest in emergency preparedness, bringing life-saving hemorrhage control out of clinical settings and into everyday environments.

“Preparedness should be accessible to everyone,” said Wayne Grube, CEO and Co-Founder, BC3 Technologies. “By enabling HSA and FSA eligibility, we are removing a barrier and empowering more people to be equipped for bleeding emergencies, whether at home, on the road, or in the field. When seconds matter, access matters.”

Severe bleeding remains one of the leading causes of preventable death in trauma. While traditional first aid solutions are widely available, rapid and effective hemorrhage control tools have historically been limited to professional or institutional settings. The addition of HSA/FSA eligibility represents a significant step toward expanding access to advanced bleeding control solutions for everyday use.

SEAL Hemostatic Wound Spray is a first-of-its-kind, FDA-cleared aerosolized chitosan delivery system designed for rapid assist in controlling severe external bleeding. Its dry-powder spray technology allows for fast, even application across irregular wound surfaces, forming a physical barrier that supports hemorrhage control when used with direct pressure.

Compact, easy to use, and effective in challenging environments, SEAL is trusted by first responders, medical professionals, military personnel, and trained civilians, and is increasingly being adopted for home, travel, workplace, and recreational use.

The expansion into HSA/FSA eligibility aligns with growing consumer awareness around preparedness and preventative health spending, as more Americans seek practical ways to use healthcare funds to protect themselves and their families in emergency situations.

Consumers can learn more about SEAL’s HSA/FSA eligibility and purchase options at:
https://www.sealwoundcare.com/pages/seal-hsa-fsa-payments

About BC3 Technologies (www.bc3tech.com)
Founded in Baltimore in 2018, BC3 Technologies is a minority-owned company revolutionizing emergency medical response and trauma care. A privately held medical device company, BC3 Technologies focuses on the development and commercialization of hemostatic products that help save lives. Fueled by the recognition of a critical gap in emergency medical care and the urgent need for efficient management of life-threatening complex bleeding, the company designed its patented technology in the first and only FDA-cleared chitosan aerosol hemostatic wound spray, SEAL. Today, SEAL is being utilized by first responders, in surgical environments, in battlefield combat, and by everyday heroes globally.

BC3 Technologies’ mission is to enhance the survivability and recovery of individuals experiencing severe bleeding, whether in a medical facility, on the battlefield, or in everyday emergencies.